Metabonomics in toxicology: a review.
Metabonomics and its many pseudonyms (metabolomics, metabolic profiling, etc.) have exploded onto the scientific scene in the past 2 to 3 years. Nowhere has the impact been more profound than within the toxicology community. Within this community there exists a great deal of uncertainty about whether metabonomics is something to count on or just the most recent technological flash in the pan. Much of the uncertainty is due to unfamiliarity with analytical and chemometric facets of the technology and the attendant fear of any "black-box." With those fears in mind, metabonomics technology is reviewed with particular emphasis on toxicologic applications in preclinical drug development. The jargon, logistics, and applications of the technology are covered in some detail with emphasis on recent work in the field.
Robertson
Donald G
DG
Metabonomics Evaluation Group, Department of World-Wide Safety Sciences, Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA. donald.robertson@pfizer.com
D000818:Animals; D015415:Biomarkers; D055598:Chemical Phenomena; D002621:Chemistry; D006168:Guinea Pigs; D009682:Magnetic Resonance Spectroscopy; D008660:Metabolism / Q000502:physiology*; D012371:Robotics; D009626:Terminology as Topic; D014116:Toxicology / Q000639:trends*
D015415:Biomarkers